Prevalence and Progression of Monoclonal Gammopathies
Prevalence and Progression of Monoclonal Gammopathies
批准号:
8692316
负责人:
SHAJI Kunnathu KUMAR
金额:
$32.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-03-01 至 2019-02-28
关键词:
AccountingAddressAfricanAfrican AmericanAgeArchivesB lymphoid malignancyBiological MarkersBloodBone MarrowCell ProliferationCessation of lifeClinicalCytogeneticsDatabasesDetectionDiagnosisDiseaseEarly DiagnosisEarly identificationEtiologyFirst Degree RelativeFluorescent in Situ HybridizationGeneral PopulationGoalsGrantHumanImmunoglobulin MImmunoglobulinsIncidenceIndividualInfectionInflammationLaboratoriesLeadLifeLightMalignant NeoplasmsMarrowMeasurementMonoclonal GammapathiesMonoclonal gammopathy of uncertain significanceMorbidity - disease rateMultiple MyelomaNatural HistoryPathogenesisPatientsPersonsPhasePlasma CellsPlayPopulationPrecancerous ConditionsPredisposing FactorPredispositionPremalignantPrevalencePrevention strategyRiskRisk AssessmentRisk FactorsRoleSamplingSerumStagingStratificationTestingTrisomyUnited StatesWorkbasecohortepidemiology studyfollow-uphigh riskimprovedinnovationkappa-Chain Immunoglobulinsmultiple myeloma M Proteinoutcome forecastpatient populationpopulation basedpublic health relevanceresponsescreening
中文摘要
描述(由申请方提供):多发性骨髓瘤(MM)是一种危及生命的浆细胞恶性肿瘤。MM有一个长期的临床可检测的恶变前阶段,称为意义不明的单克隆丙种球蛋白病(MGUS),可以通过检测分泌的单克隆免疫球蛋白(M蛋白)和通过存在异常免疫球蛋白κ/λ游离轻链(FLC)比率来识别。在过去的10年中,我们对MM的各种前体阶段进行了广泛的表征,并进行了大量研究,将FLC的单克隆升高和FLC比率的异常作为一系列浆细胞疾病的诊断、预后、缓解评估和风险分层的生物标志物。该更新的目标之一是确定MGUS发生的原因,以及多克隆浆细胞增殖对感染或炎症的反应是否在MGUS、MM和相关恶性肿瘤的发病机制中起作用。我们也在调查MM发病率种族差异的原因;例如,年轻黑人的风险比白人高3倍。我们的研究表明,种族差异的一个主要原因是黑人中前体MGUS阶段的发生率明显过高。同样,我们发现了一个显着的家族易感性MGUS和MM。由于MM由多个独特的实体从细胞遗传学的角度来看,我们需要确定精确的细胞遗传学亚型负责种族差异和家族易感性。因此,两个基本问题是:1)我们能否在恶性前MGUS阶段(前体阶段的前体)之前确定预测MM风险的生物标志物?2)在黑人和一级亲属中,哪些特定的细胞遗传学亚型导致MM风险增加?在目标1中,
确定血清免疫球蛋白FLC的多克隆升高是否与MGUS、MM和相关B细胞恶性肿瘤的风险增加相关,在一个近16,000例患者的大型队列中。在目标2中,我们将收集和研究800名黑人MM患者的队列,以确定与MM风险增加相关的MM的特定细胞遗传学亚型,并确定治疗反应和生存的预测因子。在目标3中,我们将进行研究,以确定特定的细胞遗传学亚型与家族易感性MGUS。我们相信我们的研究是高度创新的,并将对我们理解MGUS的病因,以及种族差异和家族易感性的细胞遗传学基础产生深远的影响。我们的研究将产生一种有希望的生物标志物,用于识别一般人群中MM和相关恶性肿瘤高风险患者。目标2和3将对MGUS和MM患者的管理产生重大影响,特别是非裔美国人和一级亲属或MGUS患者。
英文摘要
DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a life-threatening plasma cell malignancy. MM has a prolonged clinically detectable premalignant phase called monoclonal gammopathy of undetermined significance (MGUS) that can be identified by detection of the secreted monoclonal immunoglobulin (M protein) and through the presence of an abnormal immunoglobulin kappa/lambda free light chain (FLC) ratio. Over the last 10 years we have extensively characterized the various precursor stages of MM, and conducted numerous studies establishing monoclonal elevations of FLC and abnormalities in the FLC ratio as biomarkers for diagnosis, prognosis, response assessment, and risk stratification across a spectrum of plasma cell disorders. One of the goals of this renewal is to determine why MGUS occurs, and whether polyclonal plasma cell proliferation in response to infection or inflammation plays a role in pathogenesis of MGUS, MM and related malignancies. We are also investigating the reasons for dramatic racial disparity in incidence of MM; young blacks for example have a 3-fold higher risk than whites. Our studies show that a major reason for the racial discrepancy is a marked excess in the incidence of the precursor MGUS phase in blacks. Similarly, we have uncovered a significant familial predisposition in MGUS and MM. Since MM consists of multiple unique entities from a cytogenetic standpoint, we need to determine the precise cytogenetic subtypes responsible for racial disparity and familial predisposition. Thus two fundamental questions are: 1) Can we identify biomarkers that predict risk of MM prior to the premalignant MGUS stage (precursor of the precursor stage)? 2) What are the specific cytogenetic subtypes that account for the increased risk of MM in blacks and in first degree-relatives? In Aim 1 we will
determine if polyclonal elevations of serum immunoglobulin FLC are associated with an increased risk of MGUS, MM and related B cell malignancies in a large cohort of nearly 16,000 patients. In Aim 2 we will assemble and study a cohort of 800 blacks with MM to identify the specific cytogenetic subtype(s) of MM associated with increased risk of MM, and also identify predictors of response to therapy and survival. In Aim 3 we will conduct studies to identify the specific cytogenetic subtypes associated with familial predisposition in MGUS. We believe our studies are highly innovative, and will have a far-reaching impact on our understanding of the etiology of MGUS, and the cytogenetic basis for racial disparity and familial predisposition. Our studies will result in a promising biomarker to identify patients at high risk for MM and related malignancies in the general population. Aims 2 and 3 will have a major impact on the management of patients with MGUS and MM, especially African Americans and first-degree relatives or persons with MGUS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Cereblon Pathways in Myeloma
-
批准号:9024349
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2014
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
The Role of Cereblon Pathways in Myeloma
-
批准号:8669613
-
项目类别:
-
资助金额:$49.46万
-
财政年份:2014
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8342326
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8512677
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10206030
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10656463
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8846552
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10471179
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Prevalence and Progression of Monoclonal Gammopathies
-
批准号:9015415
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10362661
-
项目类别:
-
资助金额:$55.8万
-
财政年份:1997
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10113628
-
项目类别:
-
资助金额:$55.79万
-
财政年份:1997
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
海外基金